Regeneron, which Trump hailed as ‘key’ to his recovery cuts risk of COVID hospitalization and death by 70%, trial show

Regeneron’s coronavirus antibody cocktail is effective at treating mild to moderate cases of COVID-19, new late-stage trial results suggest.

The treatment is a mixture of drugs casirivimab and imdevimab, and was developed by the New York City-based company in partnership with pharmaceutical firm Roche.

Top Stories

    Leave a Reply

    Your email address will not be published. Required fields are marked *